Art. -Nr.: HY-15353

Emivirine

(Synonyms: MKC-442)

Kundenbewertung

Based on 1 Customer Validation

Emivirine (MKC-442) is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) with K_i values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.73%
CAS. Nr.: 149950-60-7
Formel: C₁₇H₂₂N₂O₃
Molecular Weight:302.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Emivirine Chemical Structure

CAS. Nr.: 149950-60-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	>100 μM Compound: MKC-442	Cytotoxic concentration was measured in CEM wild-type/thymidine-kinase-deficient CEM Cells Cytotoxic concentration was measured in CEM wild-type/thymidine-kinase-deficient CEM Cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	>10 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in thymidine-kinase-deficient CEM cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in thymidine-kinase-deficient CEM cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	>10 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in thymidine-kinase-deficient CEM cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in thymidine-kinase-deficient CEM cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	>10 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in CEM wild type cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in CEM wild type cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	>10 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in thymidine-kinase-deficient CEM cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-2 multiplication in thymidine-kinase-deficient CEM cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	>100 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in CEM wild type cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 strain N119 multiplication in CEM wild type cells	[PMID: 15715487]
CCRF-CEM	EC₅₀	0.03 μM Compound: MKC-442	Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in CEM wild type cells Effective concentration of compound to inhibit human immunodeficiency virus HIV-1 wild type strain IIIB multiplication in CEM wild type cells	[PMID: 15715487]
HeLa	CC₅₀	>100 μM Compound: MKC-442 emivirine	Compound was tested for its cytotoxicity depending on the viability of mock-infected cells Compound was tested for its cytotoxicity depending on the viability of mock-infected cells	[PMID: 10579814]
HeLa	EC₅₀	0.001 μM Compound: MKC-442 emivirine	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3 Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3	[PMID: 10579814]
HeLa	EC₅₀	0.004 μM Compound: MKC-442 emivirine	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB	[PMID: 10579814]
HeLa	EC₅₀	1.26 μM Compound: MKC-442 emivirine	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like NL4-3K103N	[PMID: 10579814]
HeLa	EC₅₀	13.4 μM Compound: MKC-442 emivirine	Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C) Compound was tested for its inhibition of HIV-1 induced focus formation in MAGI-CCR5 cells in strains like IIIB-R(Y181C)	[PMID: 10579814]
MT4	CC₅₀	>100 μM Compound: MKC-442	Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay	[PMID: 17904371]
MT4	CC₅₀	>100 μM Compound: MKC442, Emivirine	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	CC₅₀	100 μM Compound: MKC-442	Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells	[PMID: 15715487]
MT4	CC₅₀	102 μM Compound: 33	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain	[PMID: 7636846]
MT4	CC₅₀	102 μM Compound: 33	The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain	[PMID: 7636846]
MT4	CC₅₀	186 μM Compound: 33	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50% Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 7636846]
MT4	CC₅₀	200 μM Compound: MKC-422	Cytotoxicity against MT-4 cells. Cytotoxicity against MT-4 cells.	[PMID: 11472208]
MT4	CC₅₀	200 μM Compound: MKC-442	Cytotoxicity against mock-infected MT-4 cells. Cytotoxicity against mock-infected MT-4 cells.	[PMID: 10052969]
MT4	CC₅₀	200 μM Compound: MKC-442	Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells	[PMID: 14761194]
MT4	EC₅₀	>10 μM Compound: MKC442, Emivirine	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>100 μM Compound: MKC442, Emivirine	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>102 μM Compound: 33	The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD	[PMID: 7636846]
MT4	EC₅₀	0.003 μM Compound: 33	The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain	[PMID: 7636846]
MT4	EC₅₀	0.0042 μM Compound: 33	Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus. Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.	[PMID: 7636846]
MT4	EC₅₀	0.03 μM Compound: MKC442, Emivirine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.03 μM Compound: MKC-422	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	[PMID: 11472208]
MT4	EC₅₀	0.03 μM Compound: MKC-442	Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity. Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity.	[PMID: 10052969]
MT4	EC₅₀	0.03 μM Compound: MKC-442	Effective dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathogenicity Effective dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathogenicity	[PMID: 14761194]
MT4	EC₅₀	0.06 μM Compound: MKC442, Emivirine	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.08 μM Compound: MKC442, Emivirine	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	1.5 μM Compound: MKC442, Emivirine	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	100 μM Compound: MKC442, Emivirine	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	IC₅₀	0.008 μM Compound: MKC-442 emivirine	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.032 μM Compound: MKC-442 emivirine	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.1 μM Compound: MKC-442 emivirine	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	[PMID: 14643315]
PBL	CC₅₀	90 μM Compound: 33	The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain	[PMID: 7636846]

In Vitro

Emivirine (EMV) is also specific for HIV-1 RT and was without effect on HIV-2^[2].
Emivirine (EMV) has no obvious toxicity for human healthy cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Human bone marrow cells collected from normal healthy volunteers.
Concentration:

0, 0.1, 1, 10, or 100 μM.
Incubation Time:

14 days.
Result:

At concentrations of 0.1 to 10 μM, no effect on cell growth, lactic acid production, mitochondrial DNA synthesis, or mitochondrial structure was seen compared to what occurred with untreated HepG2 cells.

In Vivo

Tthe approximate lethal oral dose of Emivirine (EMV) for rats was ≥3 g/kg for males and 2.5 g/kg for females^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats^[2].
Dosage:

50 mg/kg.
Administration:

Gavage.
Result:

The oral absorption was 68%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 149950-60-7
Appearance Solid
Molecular Weight 302.37
Formel C₁₇H₂₂N₂O₃
Color White to off-white
SMILES

O=C1NC(C(C(C)C)=C(CC2=CC=CC=C2)N1COCC)=O
Synonyms

MKC-442
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (330.72 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3072 mL

16.5360 mL

33.0721 mL

5 mM

0.6614 mL

3.3072 mL

6.6144 mL

10 mM

0.3307 mL

1.6536 mL

3.3072 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Panita Decha, et al. Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions. J Enzyme Inhib Med Chem. 2011 Feb;26(1):29-36. [Content Brief]

[2]. G M Szczech, et al. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3072 mL	16.5360 mL	33.0721 mL	82.6802 mL
	5 mM	0.6614 mL	3.3072 mL	6.6144 mL	16.5360 mL
	10 mM	0.3307 mL	1.6536 mL	3.3072 mL	8.2680 mL
	15 mM	0.2205 mL	1.1024 mL	2.2048 mL	5.5120 mL
	20 mM	0.1654 mL	0.8268 mL	1.6536 mL	4.1340 mL
	25 mM	0.1323 mL	0.6614 mL	1.3229 mL	3.3072 mL
	30 mM	0.1102 mL	0.5512 mL	1.1024 mL	2.7560 mL
	40 mM	0.0827 mL	0.4134 mL	0.8268 mL	2.0670 mL
	50 mM	0.0661 mL	0.3307 mL	0.6614 mL	1.6536 mL
	60 mM	0.0551 mL	0.2756 mL	0.5512 mL	1.3780 mL
	80 mM	0.0413 mL	0.2067 mL	0.4134 mL	1.0335 mL
	100 mM	0.0331 mL	0.1654 mL	0.3307 mL	0.8268 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Emivirine

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Human Metabolite Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Emivirine

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Human Metabolite Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Emivirine Related Classifications

HY-15353 Related Classifications